Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients

Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use. In animals, pegylated liposomal mitomycin C lipid-based prodrug (PL-MLP) was well tolerated and more effective than free MMC. We evaluated PL-MLP in patients with advanced cancer. Twenty-seven patients were trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Talia, Grenader, Tal, Ohana, Patricia, Amitay, Yasmine, Shmeeda, Hilary, La-Beck, Ninh M, Tahover, Esther, Berger, Raanan, Gabizon, Alberto A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618618/
https://www.ncbi.nlm.nih.gov/pubmed/26172205
http://dx.doi.org/10.1002/cam4.491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618618/
https://www.ncbi.nlm.nih.gov/pubmed/26172205
http://dx.doi.org/10.1002/cam4.491

Ejemplares similares